Diabetes Care, Vol 19, Issue 8 857-863, Copyright © 1996 by American Diabetes Association

ARTICLES

Glucagon-like peptide I enhances the insulinotropic effect of glibenclamide in NIDDM patients and in the perfused rat pancreas

MK Gutniak, L Juntti-Berggren, PM Hellstrom, A Guenifi, JJ Holst and S Efendic
Department of Endocrinology and Diabetology, Karolinska Institute, Stockholm, Sweden.

OBJECTIVE: To investigate the acute effects of glibenclamide and glucagon-like peptide I (GLP-I) and their combination in perfused isolated rat pancreas and in patients with secondary failure to sulfonylureas. RESEARCH DESIGN AND METHODS: Rat islets were perfused with 10 nmol/l GLP-I in combination with 2 mumol/l glibenclamide. In human experiments, GLP-I (0.75 pmol. kg-1.min-1) was given as a continuous infusion during 240 min, while glibenclamide (3.5 mg) was administered orally. Eight patients participated in the study (age 57.6 +/- 2.7 years, BMI 28.7 +/- 1.5 kg/m2, mean +/- SE). In all subjects, blood glucose was first normalized by insulin infusion administered by an artificial pancreas (Biostator). RESULTS: GLP-I increased the insulinotropic effect of glibenclamide fourfold in the perfused rat pancreas. In human experiments, treatment with GLP-I alone and in combination with glibenclamide significantly decreased basal glucose levels (5.1 +/- 0.4 and 4.5 +/- 0.1 vs. 6.0 +/- 0.3 mmol/l, P < 0.01), while with only glibenclamide, glucose concentrations remained unchanged. GLP-I markedly decreased total integrated glucose response to the meal (353 +/- 60 vs. 724 +/- 91 mmol.l-1. min-1, area under the curve [AUC] [-30-180 min], P < 0.02), whereas glibenclamide had no effect (598 +/- 101 mmol.l-1. min-1, AUC [-30-180 min], NS). The combined treatment further enhanced the glucose lowering effect of GLP-I (138 +/- 24 mmol. l-1.min, AUC [-30-180 min], P < 0.001). GLP-I, glibenclamide, and combined treat-stimulated meal-induced insulin release as reflected by insulinogenic indexes (control 1.44 +/- 0.4; GLP-I 6.3 +/- 1.6, P < 0.01; glibenclamide 6.8 +/- 2.1, P < 0.01; combination 20.7 +/- 5.0, P < 0.001). GLP-I inhibited basal but not postprandial glucagon responses. Using paracetamol as a marker for gastric emptying rate of the test meal, treatment with GLP-I decreased gastric emptying at 180 min by approximately 50% compared with the control subjects (P < 0.01). CONCLUSIONS: In acute experiments on overweight patients with NIDDM, GLP-I exerted a marked antidiabetogenic action on the basal and postprandial state. The peptide stimulated insulin, suppressed basal glucagon release, and prolonged gastric emptying. The glucose-lowering effect of GLP-I was further enhanced by glibenclamide. This action may be at least partially accounted for by a synergistic effect of these two compounds on insulin release. Glibenclamide per se enhanced postprandial but not basal insulin release and exerted a less pronounced antidiabetogenic effect compared with GLP-I.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				J. J. Holst The Physiology of Glucagon-like Peptide 1 Physiol Rev, October 1, 2007; 87(4): 1409 - 1439. [Abstract] [Full Text] [PDF]

				J. de Heer and J. J. Holst Sulfonylurea Compounds Uncouple the Glucose Dependence of the Insulinotropic Effect of Glucagon-Like Peptide 1 Diabetes, February 1, 2007; 56(2): 438 - 443. [Abstract] [Full Text] [PDF]

				K. Yamazaki, N. Yasuda, T. Inoue, E. Yamamoto, Y. Sugaya, T. Nagakura, M. Shinoda, R. Clark, T. Saeki, and I. Tanaka Effects of the Combination of a Dipeptidyl Peptidase IV Inhibitor and an Insulin Secretagogue on Glucose and Insulin Levels in Mice and Rats J. Pharmacol. Exp. Ther., February 1, 2007; 320(2): 738 - 746. [Abstract] [Full Text] [PDF]

				N. H McClenaghan, P. R Flatt, and A. J Ball Actions of glucagon-like peptide-1 on KATP channel-dependent and -independent effects of glucose, sulphonylureas and nateglinide. J. Endocrinol., September 1, 2006; 190(3): 889 - 896. [Abstract] [Full Text] [PDF]

				J. J. Holst and C. Orskov The Incretin Approach for Diabetes Treatment: Modulation of Islet Hormone Release by GLP-1 Agonism Diabetes, December 1, 2004; 53(suppl_3): S197 - S204. [Abstract] [Full Text] [PDF]

				J. J. Holst and J. Gromada Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans Am J Physiol Endocrinol Metab, August 1, 2004; 287(2): E199 - E206. [Abstract] [Full Text] [PDF]

				P G Kopelman and C Grace New thoughts on managing obesity Gut, July 1, 2004; 53(7): 1044 - 1053. [Full Text] [PDF]

				D. J. Drucker Enhancing Incretin Action for the Treatment of Type 2 Diabetes Diabetes Care, October 1, 2003; 26(10): 2929 - 2940. [Abstract] [Full Text] [PDF]

				S. Quddusi, T. P. Vahl, K. Hanson, R. L. Prigeon, and D. A. D'Alessio Differential Effects of Acute and Extended Infusions of Glucagon-Like Peptide-1 on First- and Second-Phase Insulin Secretion in Diabetic and Nondiabetic Humans Diabetes Care, March 1, 2003; 26(3): 791 - 798. [Abstract] [Full Text] [PDF]

				G. S. Meneilly, C. H.S. McIntosh, R. A. Pederson, J. F. Habener, R. Gingerich, J. M. Egan, D. T. Finegood, and D. Elahi Effect of Glucagon-Like Peptide 1 on Non-Insulin-Mediated Glucose Uptake in the Elderly Patient With Diabetes Diabetes Care, November 1, 2001; 24(11): 1951 - 1956. [Abstract] [Full Text] [PDF]

				D. J. Drucker Minireview: The Glucagon-Like Peptides Endocrinology, February 1, 2001; 142(2): 521 - 527. [Abstract] [Full Text] [PDF]

				T. J. Kieffer and J. Francis Habener The Glucagon-Like Peptides Endocr. Rev., December 1, 1999; 20(6): 876 - 913. [Abstract] [Full Text]

				E. Naslund, J. Bogefors, S. Skogar, P. Gryback, H. Jacobsson, J. J. Holst, and P. M. Hellstrom GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans Am J Physiol Regulatory Integrative Comp Physiol, September 1, 1999; 277(3): R910 - R916. [Abstract] [Full Text] [PDF]